Abstract
Despite the complex and unpredictable nature of pathogen occurrence, substantial efforts have been made to better predict infectious diseases (IDs). Following PRISMA guidelines, we conducted a systematic review to investigate the advances in ID prediction capabilities for human and animal diseases, focusing on Machine Learning (ML) and Deep Learning (DL) techniques. Between January 2001 and May 2021, the number of relevant articles published steadily increased with a significantly influx after January 2019. Among the 237 articles included, a variety of IDs and locations were modeled, with the most common being COVID-19 (37.1%) followed by Influenza/influenza-like illnesses (8.9%) and Eastern Asia (32.5%) followed by North America (17.7%), respectively. Tree-based ML models (38.4%) and feed-forward DL neural networks (26.6%) were the most frequent approaches taking advantage of a wide variety of input features. Most articles contained models predicting temporal incidence (66.7%) followed by disease risk (38.0%) and spatial movement (31.2%). Less than 10% of studies addressed the concepts of uncertainty quantification, computational efficiency, and missing data, which are essential to operational use and deployment. Our study summarizes the broad aspects and current status of ID prediction capabilities and provides guidelines for future works to better support biopreparedness and response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Defense Threat Reduction Agency (project number CB11029)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analyzed during this review are included in this article and its supplementary information files
